MDR1 genotypes do not influence the absorption of a single oral dose of 600 mg valacyclovir in healthy Chinese Han ethnic males

British Journal of Clinical Pharmacology

Volumn 66, Issue 2, 2008, Pages 247-254

  Zhang, Yan ^a   Jiang, Xue Hua ^a   Hu, Yu Qin ^a   Li, Zhi Ru ^b   Su, Lan ^b   Wang, Zhan Guo ^a   Ma, Guo ^a  

^a SICHUAN UNIVERSITY   (China)

^b Chengdu Blood Centre   (China)

Author keywords

Absorption; Genotype; Haplotype; MDR1; P glycoprotein; Valacyclovir

Indexed keywords

ACICLOVIR; MULTIDRUG RESISTANCE PROTEIN 1; VALACICLOVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHINESE; DRUG ABSORPTION; DRUG BLOOD LEVEL; ETHNIC GROUP; EXON; GENE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC LINKAGE; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; MDR1 GENE; NORMAL HUMAN; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 47249085145     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03189.x     Document Type: Article

References (26)

1. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product p-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987 84 : 7735 8.
2. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 1990 38 : 1277 87.
3. Borst P, Schinkel AH, Smit JJ, Wagenaar E, Van Deemter L, Smith AJ, Eijdems EW, Baas F, Zaman GJ. Classical and novel forms of multidrug resistance and the physiological functions of P-glycoprotein in mammals. Pharmacol Ther 1993 60 : 289 99.
4. MacFarland A, Abramovich DR, Ewen SW, Pearson CK. Stage-specific distribution of P-glycoprotein in first-trimester and full-term human placenta. Histochem J 1994 26 : 417 23.
5. Fromm MF. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 2004 25 : 423 9.
6. Hoffmeyer S, Burk O, Von-Richter O, Arnold HP, Brockmöller J, Johne A, Cascorbi I, Gerloff T, Roots I. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000 97 : 3473 8.
7. Ameyaw MM, Regateiro F, Li T, Liu XH, Tariq M, Mobarek A, Thornton N, Folayan GO, Githang'a J, Indalo A, Ofori-Adjei D, Price-Evans DA, Mcleod HL. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001 11 : 217 21.
8. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG, Wilkinson GR. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001 70 : 189 99.
9. Balram C, Sharma A, Sivathasan C, Edmund J, Lee D. Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic-genotypic correlates. Br J Clin Pharmacol 2003 56 : 78 83.
10. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: from genomics to mechanism. Oncogene 2003 22 : 7468 85.
11. Tang K, Ngoi SM, Gwee PC, Chua JM, Lee EJ, Chong SS, Lee CG. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 2002 12 : 437 50.
12. Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, Young JD, Taylor T, Carlson EJ, Herskowitz I, Giacomini KM, Clark AG. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003 13 : 481 94.
13. Shon JH, Yoon YR, Hong WS, Nguyen PM, Lee SS, Choi YG, Cha IJ, Shin JG. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. Clin Pharmacol Ther 2005 78 : 191 201.
14. Zhang WX, Chen GL, Zhang W, Tan ZR, Liu J, Zhou G, Hu DL, Zhou HH. MDR1 genotype does not influence the absorption of a single oral dose of 100 mg talinolol in healthy Chinese males. Clin Chim Acta 2005 359 : 46 52.
15. Kerb R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett 2006 234 : 4 33.
16. Landowski CP, Sun D, Foster DR, Menon SS, Barnett JL, Welage LS, Ramachandran C, Amidon GL. Gene expression in the human intestine and correlation with oral valacyclovir pharmacokinetic parameters. J Pharmacol Exp Ther 2003 306 : 778 86.
17. Palmberger TF, Hombach J, Bernkop-Schnürch A. Thiolated chitosan: development and in vitro evaluation of an oral delivery system for acyclovir. Int J Pharm 2008 348 : 54 60.
18. Sunder-Plassmann R, Rieger S, Endler G, Brunner M, Müller M, Mannhalter C. Simultaneous analysis of MDR1 C3435T, G2677T/A, and C1236T genotypes by multiplexed mutagenically separated PCR. Clin Chem Lab Med 2005 43 : 192 4.
19. Johne A, Köpke K, Gerloff T, Mai I, Rietbrock S, Meisel C, Hoffmeyer S, Kerb R, Fromm MF, Brinkmann U, Eichelbaum M, Brockmöller J, Cascorbi I, Roots I. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther 2002 72 : 584 94.
20. Mai I, Perloff ES, Bauer S, Goldammer M, Johne A, Filler G, Budde K, Roots L. MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients. Br J Clin Pharmacol 2004 58 : 548 53.
21. Beutner KR. Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. Antivir Res 1995 28 : 281 90.
22. Miserocchi E, Modorati G, Galli L, Rama P. Efficacy of valacyclovir vs acyclovir for the prevention of recurrent herpes simplex virus eye disease: a pilot study. Am J Ophthalmol 2007 144 : 547 51.
23. Peyrière H, Branger B, Bengler C, Vécina F, Pinzani V, Hillaire-Buys D, Blayac JP. Neurotoxicity induced by valacyclovir in three patients with impaired renal function, overdose related to the improvement of the bioavailability of the drug? Rev Med Intern 2001 22 : 297 33.
24. Bardin C, Hamel A, Pichard A, Havard L. Relation between concentration and toxicity of the anti-herpesvirus drugs. Pharmacocinétique des médicaments anti-infectieux 2004 365 : 53 7.
25. Duquesnoy C, Lacey LF, Keene ON, Bye A. Evaluation of different partial AUCs as indirect measures of rate of drug absorption in comparative pharmacokinetic studies. Eur J Pharm Sci 1998 6 : 259 63.
26. Endrenyi L, Csizmadia F, Tothfalusi L, Chen ML. Metrics comparing simulated early concentration profile for the determination of bioequivalence. Pharm Res 1998 15 : 1292 9.